JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120923

Leelamine, Pyruvate dehydrogenase kinase (PDK) inhibitor

Be the first to review this product! Submit a review

|

(0 Publication)

MW 285.47 g/mol, Purity >98%. Pyruvate dehydrogenase kinase (PDK) inhibitor (IC50 = 9.5 μM). It has weak affinity for human CB1 and CB2 receptors, exhibiting 20% displacement of [3H]-CP55940 at a concentration of 10 μM.
1 Images
Chemical Structure - Leelamine, Pyruvate dehydrogenase kinase (PDK) inhibitor (AB120923)
  • Chemical Structure

Lab

Chemical Structure - Leelamine, Pyruvate dehydrogenase kinase (PDK) inhibitor (AB120923)

2D chemical structure image of ab120923, Leelamine, Pyruvate dehydrogenase kinase (PDK) inhibitor

Key facts

CAS number

1446-61-3

Purity

>98%

Form

Liquid

form

Molecular weight

285.47 g/mol

Molecular formula

C<sub>2</sub><sub>0</sub>H<sub>3</sub><sub>1</sub>N

Nature

Synthetic

Biological description

Pyruvate dehydrogenase kinase (PDK) inhibitor (IC50 = 9.5 μM). It has weak affinity for human CB1 and CB2 receptors, exhibiting 20% displacement of [3H]-CP55940 at a concentration of 10 μM.

Isomeric smiles

CC(C)C(C=C1)=CC2=C1[C@]3(C)[C@](CC2)([H])[C@@](CN)(C)CCC3

IUPAC Name

(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com